Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1089]
News [2702]
Articles [179]
Editorials [9]
Conferences [110]
elearning [25]
Fasting primes gut microbiome to improve intestinal recovery after radiation treatment
Fasting primes gut microbiome to improve intestinal recovery after radiation treatment
Genome editing in rats enables more accurate ER+ breast cancer models
Genome editing in rats enables more accurate ER+ breast cancer models
Researchers discover new form of hereditary prostate cancer
Researchers discover new form of hereditary prostate cancer
FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer
FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for...
American Cancer Society reports latest global cancer statistics; Cancer cases approach 21 million worldwide, with burden projected to surge 67% by 2050
American Cancer Society reports latest global cancer statistics; Cancer cases approach 21 million worldwide, with...
Study paves the way for a new drug against metastatic prostate cancer
Study paves the way for a new drug against metastatic prostate cancer
Rare benign kidney tumour case highlights value of biopsy and minimally invasive treatment
Rare benign kidney tumour case highlights value of biopsy and minimally invasive treatment
Parsing the pathology of prostate cancer
Parsing the pathology of prostate cancer
Low grip strength should not be used as an independent predictor of prostate cancer in older men
Low grip strength should not be used as an independent predictor of prostate cancer in older men
European Commission approves enfortumab vedotin in combination with pembrolizumab as the first and only approved perioperative treatment option for cisplatin-ineligible patients with resectable muscle-invasive bladder cancer
European Commission approves enfortumab vedotin in combination with pembrolizumab as the first and only approved...

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation